Stem cells can be serious business, but sometimes stories come along that are just fun like a lady running a marathon dressed as a stem cell. How cool is this: “Louise Cato from Somerset is doing the run to raise money for the charity Anthony Nolan, after her dad had a bone marrow transplant over […]
Weekly reads: stem cell marathon, Ray Therapeutics, stem cells making you fat? Read More »
What’s life as an academic scientist really like now? It’s gotten worse in the U.S. recently. There’s more stress about funding including on levels that we can’t control. I’m writing too many grant proposals these days. I’m wondering how much researchers are now using AI for grant writing, which I have not done. Does AI
Weekly reads: robot scientist, stem cell sperm make a baby, assembloids & sense Read More »
I want to discuss a recent development with Humacyte and the FDA, but first, please check out a new video below that is a discussion between student Parmin Sedigh and me on the idea of stem cells for heart disease. Parmin has also written for The Niche and has her own site too. I am impressed
Weekly reads: Humacyte, retinal stem cells, stem cell therapy for knees & hearts Read More »
Most of us want longevity, especially if our quality of life remains generally solid as we age. The combination of length and quality of life is sometimes called “healthspan.” How do we get the maximum health span? Easier said than done. Not all of the obstacles are biological either. Unfortunately, accompanying all the legitimate research
Weekly reads: Topol on longevity biz, Peter Marks out at FDA, timeless NIH grant advice Read More »
Chinese CRISPR research continues to grow and this includes interesting CRISPR biotech firms. Some here in the U.S. worry that American gene editing firms could be lagging behind. Especially over the past year, investors and even some scientists have voiced frustration. U.S. gene editing firms like Editas have been struggling for years. Its stock is
Weekly reads: Chinese CRISPR biotechs, cultured meat war, MSCs for Alzheimer’s Read More »
I had a feeling late last year that I’d frequently be writing about RFK Jr. and his impact on the FDA. However, I didn’t realize some of that would be writing for STAT News. As I mentioned a few days ago, I now have a new regular column over there. I thought the column would
Weekly reads: RFK Jr. stem cell summit, FDA OKs eye cell therapy, cartilage repair Read More »
Ever heard of woolly mice? I hadn’t either until recently. The story begins with de-extinction research. De-extinction can be both cool and arguably a colossal waste of research dollars. The specific effort to de-extinct woolly mammoths fits that dual classification. Woolly mice on the road back to mammoths? Let’s dig into this with some news:
I recently looked at the organizational chart at the FDA’s Center for Biologics Evaluation and Research or CBER. Why? I have been anticipating some possible big changes there with the new administration. After all, with HHS Secretary RFK Jr. having previously claimed that the FDA was suppressing various unproven things including at least two kinds
Weekly reads: CBER changes, Parkinson’s, 2-dad mice, NIH woes continue Read More »
In all the time I’ve been a scientist I never worried about American science until the last month. Even during the first Trump administration, while there were challenges, I felt like things would generally be okay. Research continued. One of my daughters and I went to the Science March in 2017 in Sacramento. We bumped
Weekly reads: blowtorch to American science, stem cells for teeth & stroke Read More »
It’s been an exhausting week for anyone who cares about the NIH and biomedical research, but in today’s weekly reads I want to talk about another kind of fatigue: stem cell exhaustion. Please subscribe to The Niche Before we get into that, I’d like to ask a favor: please subscribe to this site, The Niche.
Weekly reads: stem cell exhaustion, Lineage Cell trial, Iowa AG wins vs. clinics Read More »